RemeGen (HKG:9995, SHA:688331) obtained a drug registration certificate and marketing approval for a new indication of Telitacicept for Injection from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.
The new indication of the drug is for the treatment of Sjögren's syndrome, the biopharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments